High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Chen, Xiaojing ^a   Sun, Kai ^a   Jiao, Shufan ^a   Cai, Ning ^a   Zhao, Xue ^a   Zou, Hanbing ^a   Xie, Yuexia ^a   Wang, Zhengshi ^a   Zhong, Ming ^a   Wei, Lixin ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TUMOR MARKER;

ADULT; AGED; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER STAGING; CANCER STEM CELL; CELL PROLIFERATION; CELL TRANSFORMATION; COLORECTAL TUMOR; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MOUSE; NUDE MOUSE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIRTUIN 1; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929443198     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07481     Document Type: Article

References (56)

1. Cunningham, D. et al. Colorectal cancer. Lancet 375, 1030-47 (2010).
2. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-67 (1990).
3. Fearon, E. R. & Jones, P. A. Progressing toward a molecular description of colorectal cancer development. FASEB J 6, 2783-90 (1992).
4. Radtke, F. & Clevers, H. Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904-9 (2005).
5. Watson, A. J. & Collins, P. D. Colon cancer: a civilization disorder. Dig Dis 29, 222-8 (2011).
6. Siegel, R., Desantis, C. & Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J Clin 64, 104-17 (2014).
7. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013).
8. Nelson, H. et al.Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93, 583-96 (2001).
9. O'Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. JNatl Cancer Inst 96, 1420-5 (2004).
10. O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-10 (2007).
11. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-11 (2001).
12. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-84 (2005).
13. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-60 (2006).
14. Diehn, M. et al.Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-3 (2009).
15. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancerinitiating cells. Nature 445, 111-5 (2007).
16. Cohen, H. Y. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-2 (2004).
17. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-59 (2001).
18. Luo, J. et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107, 137-48 (2001).
19. Li, Y. et al. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ 14, 2058-67 (2007).
20. Wang, C. et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8, 1025-31 (2006).
21. Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53- induced cellular senescence. EMBO J 21, 2383-96 (2002).
22. Audrito, V. et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 71, 4473-83 (2011).
23. Han, M. K. et al. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2, 241-51 (2008).
24. Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-5 (2004).
25. Brooks, C. L. & Gu, W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9, 123-8 (2009).
26. Liu, T., Liu, P. Y. & Marshall, G. M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69, 1702-5 (2009).
27. Huffman, D. M. et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67, 6612-8 (2007).
28. Kuzmichev, A. et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A 102, 1859-64 (2005).
29. Elangovan, S. et al. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor alpha in breast cancer. Cancer Res 71, 6654-64 (2011).
30. Song, N. Y. & Surh, Y. J. Janus-faced role of SIRT1 in tumorigenesis. AnnNYAcad Sci 1271, 10-9 (2012).
31. Ou, X. et al. SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood 117, 440-50 (2011).
32. Zhang, Z. N., Chung, S. K., Xu, Z. & Xu, Y. Oct4 maintains the pluripotency of human embryonic stem cells by inactivating p53 through Sirt1-mediated deacetylation. Stem Cells 32, 157-65 (2014).
33. Fargeas, C. A., Corbeil, D. & Huttner, W. B. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells 21, 506-8 (2003).
34. Vermeulen, L. et al. Single-cell cloning of colon cancer stem cells reveals a multilineage differentiation capacity. Proc Natl Acad Sci U S A 105, 13427-32 (2008).
35. Price, J. E., Polyzos, A., Zhang, R. D. & Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50, 717-21 (1990).
36. Hong, H. et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-5 (2009).
37. Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-81 (2012).
38. Deng, C. X. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 5, 147-52 (2009).
39. Bosch-Presegue, L. & Vaquero, A. The dual role of sirtuins in cancer. Genes Cancer 2, 648-62 (2011).
40. Liu, G. et al. Analysis of gene expression and chemoresistance of CD1331 cancer stem cells in glioblastoma. Mol Cancer 5, 67 (2006).
41. Hida, Y., Kubo, Y., Murao, K. & Arase, S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 299, 103-6 (2007).
42. Pruitt, K. et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2, e40 (2006).
43. Yu, E. J. et al. Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor alpha activity and co-activator synergy. Nucleic Acids Res 39, 6932-43 (2011).
44. Sasca, D. et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 124, 121-33 (2014).
45. Wang, R. H. et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14, 312-23 (2008).
46. Menssen, A. et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1- inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A 109, E187-96 (2012).
47. Marhold, M. et al. HIF-1alpha Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. Mol Cancer Res Oct 27, early online (2014).
48. Wang, D. et al. Oct-4 and nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget Oct 4, early online (2014).
49. Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7, 979-87 (2008).
50. Akita, H. et al. MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism. Cancer Res 74, 5903-13 (2014).
51. Chen, W. Y. et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123, 437-48 (2005).
52. Prives, C. & Manley, J. L. Why is p53 acetylated? Cell 107, 815-8 (2001).
53. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-26 (2008).
54. Boyer, L. A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947-56 (2005).
55. Niwa, H., Miyazaki, J. & Smith, A. G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-6 (2000).
56. Wang, L. X., Wang, J., Qu, T. T., Zhang, Y. & Shen, Y. F. Reversible acetylation of Lin28 mediated by PCAF and SIRT1. Biochim Biophys Acta 1843, 1188-95 (2014).